Cigna denied my wife's stage III breast cancer reconstruction claiming the contralateral prophylactic mastectomy was 'cosmetic' even though her BRCA2-positive status and the WHCRA mandate the coverage. Overturned in 14 days using a Section 502(a)(1)(B) ERISA appeal letter, the WHCRA citation, and the NCCN Guidelines. The federal-law framework that breaks 'cosmetic' denials cold

Posting this because the "cosmetic procedure" denial is one of the most common and most legally indefensible bad-faith tactics carriers use against breast cancer reconstruction claims, and the federal statutory protections are so specific and so powerful that the denials almost always collapse the moment the policyholder cites the controlling law. Background: my wife was diagnosed with stage IIIA invasive ductal carcinoma of the right breast in November 2025 with confirmed BRCA2-positive status on germline genetic testing performed at the time of diagnosis. Her surgical oncology team at MD Anderson recommended a bilateral mastectomy (therapeutic right, contralateral prophylactic left) followed by immediate DIEP flap reconstruction in a single-stage procedure. The contralateral prophylactic mastectomy was clinically indicated based on her BRCA2 mutation which carries a lifetime contralateral breast cancer risk of 40 to 60 percent, supported by the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024) and the ASBrS Consensus Statement on Prophylactic Mastectomy.

Cigna pre-authorized the right (therapeutic) mastectomy and the right-side reconstruction without issue but denied pre-authorization for the left (contralateral prophylactic) mastectomy and the left-side reconstruction on the basis that "contralateral prophylactic procedures and the associated reconstruction are cosmetic in nature and not medically necessary for the treatment of the diagnosed malignancy." The denial letter explicitly invoked Cigna's internal medical policy R02 on Reconstructive Surgery which excludes "procedures intended primarily to alter appearance" from coverage. The denial was patently unlawful on its face because it ignored the controlling federal statute (the Women's Health and Cancer Rights Act of 1998, 29 U.S.C. Section 1185b) which mandates coverage for reconstruction of the affected breast, surgery and reconstruction of the other breast to produce a symmetrical appearance, prostheses, and treatment of physical complications including lymphedema, in any plan that covers mastectomies.

The federal-law framework that breaks 'cosmetic' denials cold. First, the WHCRA citation. The Women's Health and Cancer Rights Act applies to any group health plan or individual market plan that covers mastectomies (essentially every plan in the United States) and mandates coverage for both reconstruction of the affected breast and surgery on the unaffected breast to produce symmetrical appearance. The statute is not subject to medical necessity review for the symmetry procedure. The carrier cannot deny the contralateral procedure on "cosmetic" grounds because the statute expressly mandates coverage of symmetry procedures regardless of medical necessity. DOL regulations at 29 CFR Section 2590.715-2719A and the Affordable Care Act preventive services provisions reinforce this coverage mandate. Second, the BRCA2-specific medical necessity argument. Even if the symmetry argument were not dispositive (it is) the contralateral prophylactic mastectomy is independently medically necessary based on the BRCA2 mutation status under the NCCN Guidelines which recommend bilateral mastectomy as a risk-reduction strategy for BRCA1/2 mutation carriers with documented breast cancer diagnosis. The ASCO Clinical Practice Guideline on BRCA1/2 Testing and Management aligns with NCCN on this recommendation.

Third, the ERISA Section 502(a)(1)(B) appeal letter. For employer-sponsored plans (which covers the vast majority of breast cancer patients of working age) the claims procedure regulations at 29 CFR Section 2560.503-1 require the carrier to provide a full and fair review of any adverse benefit determination, identify the specific reasons for denial, identify the plan provisions on which the denial is based, and provide an opportunity to submit additional evidence. The appeal letter must invoke ERISA Section 502(a)(1)(B), cite the WHCRA mandate, attach the relevant NCCN and ASCO guidelines, include the treating surgical oncologist's medical necessity letter, and demand a written response within 30 days for pre-service appeals or 60 days for post-service appeals. The letter should also signal that adverse determination will be challenged in federal court under ERISA Section 502(a) and that the carrier will be exposed to attorney fees under Section 502(g) and equitable relief under Section 502(a)(3) for any improper denial. Cigna reversed the denial in 14 days on the WHCRA grounds alone without reaching the BRCA2 medical necessity argument. The procedure was performed 3 weeks later at MD Anderson and was fully covered including the contralateral reconstruction. The WHCRA citation is the single most powerful weapon in any breast reconstruction denial appeal.